Navigation Links
Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference
Date:9/9/2011

ST. PETERSBURG, Fla., Sept. 9, 2011 /PRNewswire/ -- The Advanced Wound Management division of Smith & Nephew (LSE: SN; NYSE: SNN) today announced results from 11 studies on a range of products and therapies from their ALLEVYN*, ACTICOAT*, IODOSORB* and RENASYS* wound care portfolio. The data demonstrate advanced healing strategies and the efficacy of the company's specialized advanced wound care products. Results of the studies are being presented at the Clinical Symposium on Advances in Skin & Wound Care (CSASWC), a national convention for wound care professionals.

(Photo:  http://photos.prnewswire.com/prnh/20110909/SF65366)

The results of the IODOSORB trial will be shared as a podium presentation. This was a prospective, non-comparative, multicenter study investigating the effect of IODOSORB on bioburden load and other wound characteristics in diabetic foot ulcers. Elevated bacterial burden has been cited as a contributing factor in the delayed healing of these types of ulcers. The study showed significant evidence (p=0.008) of reduction in the clinical signs of infection when IODOSORB was used.

"The study results showed that when IODOSORB was used on diabetic foot ulcers, significant reductions in wound area, levels of exudates and pain were seen in patients, as well as an improvement in wound appearance," said Dr. John Lantis II, Chief of Division, Endovascular-Vascular Surgery, Director of Clinical Research, Department of Surgery, St. Lukes-Roosevelt Hospital Center, New York and author of the research. "This is encouraging news for patients, as foot ulcers occur in nearly 15 percent of all patients with diabetes."

In addition to the new clinical data being presented at CSASWC, Smith & Nephew will also introduce the new ALLEVYN Gentle Border Multisite dressing.  Its imaginative shape is designed to fit the unique contours of the body, and stay in place.  ALLEVYN Multisite, along with ALLEVYN Gentle Border Sacrum and ALLEVYN Gentle Border Heel are uniquely shaped dressings that form the foundation for the new 'Human Shaped Wound Care' campaign.  As part of the campaign introduction, Smith & Nephew will be hosting an interactive ALLEVYN Gentle Border Multisite Challenge, at their booth (#225).

"Reducing the human and economic cost of wounds is a core value of Smith & Nephew.  We are focused on innovation and best practice techniques for the prevention and healing of wounds. Imaginative solutions like our new Human Shaped ALLEVYN dressings help improve outcomes for patients and at the same time conserve resources for health care systems," said Thomas J. Dugan, President of Smith & Nephew's North American Advanced Wound Management Division.

Additionally, Smith & Nephew will be offering Twin Towers Pins to attendees, for a $2 donation to the Twin Tower Orphan fund. The program was founded on September 11, 2001 with the sole purpose of providing educational and welfare assistance to the children who lost parents by the terrorist attacks on 9/11.

Smith & Nephew will continue its presence at tradeshows throughout the fall at:

  • Diabetic Limb Salvage conference (Sept. 22-24)
  • The American Society of Plastic Surgeons meeting (Sept. 23-27)
  • The Symposium of Advanced Wound Care (Oct. 13-15)
  • The Orthopedic Trauma Association annual meeting (Oct. 12-15)
  • Health Industry Distributers Association Conference & expo (Oct. 19-21)
  • The Canadian Association of Wound Care annual conference (Nov. 3-6).

To get the latest and timeliest news from the Advanced Wound Management division of Smith & Nephew, register at www.Twitter.com today and "follow" @woundcare.

About Smith & Nephew

Smith & Nephew is a global medical technology business with global leadership positions in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy, including Sports Medicine; and Advanced Wound Management.  Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives.  The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust.  The Company has distribution channels, purchasing agents and buying entities in over 90 countries worldwide.  Annual sales in 2010 were nearly $4.0 billion.

Forward-Looking Statements

This document may contain forward-looking statements that may or may not prove accurate.  For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements.  Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements.  Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions and our success in integrating acquired businesses; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature.  Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.

Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution.  Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

*  Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.


'/>"/>
SOURCE Advanced Wound Management division of Smith & Nephew
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. SpineSmith Partners to Present at 3rd Annual Stem Cell Summit
8. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
9. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)...   Genomic Health, Inc. (Nasdaq: GHDX ) today ... ended December 31, 2015. --> --> ... compared with $69.1 million in the fourth quarter of 2014, an ... 9 percent compared with the same period in the prior year. ... $63.9 million in the fourth quarter of 2015, an increase of ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , February 10, 2016 ... Analyzers (Liquid & Gas), and Spectroscopy Market by Industry (Oil ... Beverage, Pulp & Paper, Metal & Mining, and Others), ... MarketsandMarkets, the global market is expected to grow to ... of 8.6% between 2015 and 2020. Browse ...
Breaking Medicine Technology:
(Date:2/10/2016)... York, NY (PRWEB) , ... February 10, 2016 , ... ... campaign to celebrate and raise awareness of Nestlé KITKAT as the first global confectionery ... the lives of cocoa farmers and the quality of their product, through activities that ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... to expand dental health services to the developmentally disabled in the Coachella Valley. ... operations to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho ...
(Date:2/10/2016)... Washington (PRWEB) , ... February 10, 2016 , ... ... access and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart ... remote interpreting (VRI). , For nearly 23 years, Heart City Health Center has ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... a master charity program created to assist the local community. Pledging to select ... leaders and nonprofit organizations in the area. Their goal is to bring community ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Valley , announces that his office is now offering a variety of comprehensive ... enhancement, chin enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. ...
Breaking Medicine News(10 mins):